Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Mounjaro - labeled renal guidance
Product / population
Tirzepatide (Mounjaro), adult subcutaneous injection for type 2 diabetes
Renal method
Clinical renal category or population named in the cited section
Source revision
DailyMed SPL version 40, effective 2026-08-27; posted Sep 02, 2026
All record notes are retained here, including notes about sources not selected in this review.
Mounjaro - product and source limitations
During initiation or escalation, check renal function if significant GI adverse effects cause or could cause volume depletion. Confirm the prescribed brand.
What to reconcile: Apply only to the stated formulation, indication and renal population.
DailyMed / product prescribing information · Tirzepatide (Mounjaro), adult subcutaneous injection for type 2 diabetes
Renal method: Clinical renal category or population named in the cited section Source date: DailyMed SPL version 40, effective 2026-08-27; posted Sep 02, 2026 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
No renal dose adjustment is recommended; studied exposure included patients with ESRD. During initiation or escalation, check renal function if significant GI adverse effects cause or could cause volume depletion. Confirm the prescribed brand.
RDM73-mounjaro-official-1 · Source locator: Renal guidance: 5.5 and 8.6
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
